INDRAMEDCO (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Indraprastha Medical Corporation Limited |
|||
|
Price: ₹490.30 | ||
| 52 Week Low: ₹154.50 52 Week High: ₹529.90 |
|||
| Market Capital: 3,786.53 Crore (Smallcap) | |||
| Healthcare -> Medical Care Facilities | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: INDRAMEDCO Share Price Target For 2024
- 1.1.1: INDRAMEDCO Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: INDRAMEDCO Share Price Target For 2025
- 1.2.1: INDRAMEDCO Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: INDRAMEDCO Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: INDRAMEDCO Brief Company Overview
- 4: INDRAMEDCO Financial Performance
- 4.0.1: Is INDRAMEDCO A Good Buy For Long Term?
To predict the INDRAMEDCO's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
INDRAMEDCO Share Price Target For 2024
The line chart displays the monthly closing prices of INDRAMEDCO with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for INDRAMEDCO shares in 2024, see the table below.
INDRAMEDCO Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 516.9 (+5.42%) | Price Action: 17 Dec 2024 High |
| 2024 Target 2 | 508.9 (+3.79%) | Price Action: 16 Dec 2024 High |
| 2024 Target 1 | 503.8 (+2.75%) | Price Action: 12 Dec 2024 High |
| Current Price | 490.30 | INDRAMEDCO's share price as of 20 Dec 2024 |
| Stop Loss 1 | 481.55 (-1.79%) | Price Action: 12 Dec 2024 Low |
| Stop Loss 2 | 475.98 (-2.93%) | Fibonacci Retracement Level 71.80% |
| Stop Loss 3 | 465.8 (-5.00%) | Price Action: 13 Dec 2024 Low |
Short-Term Technical Outlook
Current Technical Position: INDRAMEDCO is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹468.82 serves as the nearest technical reference point.
Historical Returns: 3-month: +15.80% | 6-month: +107.65% | 1-year: +187.04%
INDRAMEDCO Share Price Target For 2025
The line chart displays the monthly closing prices of INDRAMEDCO with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for INDRAMEDCO shares in 2025, see the table below.
INDRAMEDCO Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 748.55 (+52.67%) | Price Action: Chart |
| 2025 Target 2 | 734.59 (+49.82%) | Fibonacci Extension Level 64.90% |
| 2025 Target 1 | 718.34 (+46.51%) | Fibonacci Extension Level 150.00% |
| Current Price | 490.30 | INDRAMEDCO's share price as of 20 Dec 2024 |
| Stop Loss 1 | 433.79 (-11.53%) | Price Action: 28 Nov 2024 Low |
| Stop Loss 2 | 429.0 (-12.51%) | Price Action: 31 Oct 2024 High |
| Stop Loss 3 | 424.35 (-13.46%) | Price Action: 19 Nov 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: INDRAMEDCO is currently trading near its 52-week high of ₹529.9, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +187.04% | 3-year: +585.73% | 5-year: +1,220.50%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
INDRAMEDCO Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹490.30 | ||
| 2024 | ₹461.61 | -5.85% | ₹468.53 |
| 2025 | ₹808.51 | +75.15% | ₹820.64 |
| 2026 | ₹1,132.45 | +40.07% | ₹1,149.44 |
| 2027 | ₹1,538.86 | +35.89% | ₹1,561.94 |
| 2028 | ₹1,698.53 | +10.38% | ₹1,724.01 |
| 2029 | ₹2,001.35 | +17.83% | ₹2,033.41 |
| 2030 | ₹2,426.20 | +21.23% | ₹2,462.59 |
| 2031 | ₹2,750.71 | +13.38% | ₹2,821.53 |
| 2032 | ₹3,249.08 | +18.12% | ₹3,297.82 |
| 2033 | ₹3,242.94 | -0.19% | ₹3,337.39 |
| 2034 | ₹3,541.08 | +9.19% | ₹3,682.20 |
| 2035 | ₹4,043.89 | +14.20% | ₹4,104.55 |
| 2036 | ₹4,368.97 | +8.04% | ₹4,531.76 |
| 2037 | ₹4,959.31 | +13.51% | ₹5,033.70 |
| 2038 | ₹4,787.35 | -3.47% | ₹4,952.41 |
| 2039 | ₹4,912.31 | +2.61% | ₹5,386.87 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
INDRAMEDCO Brief Company Overview
```html Indraprastha Medical Corporation Limited: A Healthcare Giant in India Indraprastha Medical Corporation Limited, established in 1983, is a leading provider of comprehensive hospital services in India. Based in New Delhi, the company has a strong presence across the...
country. Diverse Product Range: Indraprastha Medical offers a wide range of medical services, including sugar management, genomic medicine, elder care, cardiology, oncology, emergency care, gastroenterology, neurology, orthopedics, pediatrics, ophthalmology, and more. Industry Reputation: The company has consistently maintained a strong reputation for its quality healthcare services. Its experienced medical professionals and state-of-the-art facilities have earned it recognition as a trusted healthcare provider. Commitment to Excellence: Indraprastha Medical is committed to providing affordable and accessible healthcare to all. Its commitment to innovation and patient care ensures that its services are constantly evolving to meet the changing needs of the healthcare industry. ```INDRAMEDCO Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 3,786.53 Crore | Market valuation of INDRAMEDCO's shares. |
| Revenue (TTM) | 1,318.87 Crore | Total revenue generated by INDRAMEDCO over the past twelve months. |
| Net Income (TTM) | +1,477,799,936.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +14.99% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +11.20% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+10.40% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+29.10% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
6.24 | Company's total debt divided by total shareholder equity. |
| Total Debt | 32.74 Crore | Sum of INDRAMEDCO's current & long-term financial obligations. |
| Total Cash | 309.34 Crore | Total amount of liquid funds available to INDRAMEDCO. |
| Beta | 0.81 | Beta is less than 1 indicating that the INDRAMEDCO's price is less volatile than the market. |
Is INDRAMEDCO A Good Buy For Long Term?
Indramedco, a small-cap stock with a market capitalization of ₹3,786.53 crore, shows strong growth potential. Its 12-month net profit of ₹147.77 crore on ₹1,318.87 crore revenue, coupled with an 11.2% profit margin, is impressive. While its debt is relatively low at ₹32.74 crore against a cash balance of ₹309.34 crore, the exceptionally high past returns (153.85% in 12 months, 977.82% over 5 years) raise concerns about sustainability. Further investigation into growth drivers is needed. While the current data is positive, it's too early to definitively label it a "good buy" for long-term investors; more due diligence is recommended.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
